XTL Biopharmaceuticals Ltd. (XTLB)

$1.75

+0.15 (+9.37%)
Rating:
Recommendation:
Buy
Symbol XTLB
Price $1.75
Beta 1.035
Volume Avg. 0.01M
Market Cap 9.536M
Shares () -
52 Week Range 1.35-5.65
1y Target Est -
DCF Unlevered XTLB DCF ->
DCF Levered XTLB LDCF ->
ROE 20.62% Buy
ROA 13.98% Buy
Operating Margin -
Debt / Equity 24.10% Neutral
P/E -
P/B 1.72 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Shlomo Spokone Shalev
Healthcare
Biotechnology
NASDAQ Capital Market

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.